Prevalence of ABCC3-1767G/A Polymorphism Among Patients with Antiretroviral-associated Hepatotoxicity

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2020 Mar 27

PMID 32212330

Citations 3

Authors

HariOm Singh

Sonam Lata

Ranjana Choudhari

Tapan N Dhole

Affiliations

Soon will be listed here.

Abstract

Background: Plasma concentrations of antiretrovirals (ARVs) regimens have considerably varied in individuals of human immunodeficiency virus (HIV) because of variations in the expression of drug-metabolizing and transporter genes. Transporter genes play an important role in the disposition of drugs. Polymorphism in transporter gene (ABCC3) affects the MRP3 expression and varies the treatment outcome.

Method: We examined the polymorphism of ABCC3-1767G/A gene in a total of 165 HIV patients (out of 165 HIV patients, 34 were with and 131 were without hepatotoxicity) and 156 healthy individuals using the polymerase chain reaction-restriction fragment length polymorphism method.

Results: In univariate analysis, we found a decreased prevalence of ABCC3 1767GA, 1767GA+AA genotypes, and 1767A allele in patients with hepatotoxicity as compared to patients without hepatotoxicity (23.5% vs. 28.2% and 23.5% vs. 30.53%; 11.76% vs. 16.41%), while a higher prevalence of 1767AA genotype was observed in HIV patients in comparison with healthy controls (2.3% vs. 1.3%, odds ratio [OR] = 1.71, 95% confidence interval [CI]: 0.23-15.03, p = .89). The frequency of ABCC3-1767AA genotype was dispersed higher in individuals with early and advanced HIV disease stage in comparison with healthy controls (5.3% vs. 1.3%, OR = 4.73, p = .70; 8.9% vs. 1.3%, OR = 1.89, p = .91). A higher occurrence of ABCC3-1767AA genotype was found in tobacco using HIV patients without hepatotoxicity compared with nonusers (4.7% vs. 1.1%, OR = 4.28, p = .52). The distribution of ABCC3-1767GA genotype was higher in nevirapine receiving HIV patients irrespective of their hepatotoxicity status as compared to nonusers (30.4% vs. 9.1%, OR = 3.34, p = .22; 29.4% vs. 16.7%, OR = 1.69, p = .77). In multivariate analysis, HIV patients receiving nevirapine and with hepatotoxicity was found to have a significant risk for severity of hepatotoxicity (OR = 4.56, 95% CI: 1.60-12.99, p = .004).

Conclusion: ABCC3 1767G/A polymorphism was not significantly associated with susceptibility to ARV-associated hepatotoxicity, although ABCC3 1767AA genotype designated a risk for acquisition of hepatotoxicity and advancement of the disease. Nevirapine usage emerged as an independent risk factor for hepatotoxicity severity.

Citing Articles

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism.

Shilbayeh S, Adeen I, Ghanem E, Aljurayb H, Aldilaijan K, AlDosari F Front Pharmacol. 2024; 15:1356763.

PMID: 38375040 PMC: 10875102. DOI: 10.3389/fphar.2024.1356763.

Progress and challenges of multidrug resistance proteins in diseases.

Ding P, Gao Y, Wang J, Xiang H, Zhang C, Wang L Am J Cancer Res. 2022; 12(10):4483-4501.

PMID: 36381332 PMC: 9641395.

Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity.

Singh H, Lata S, Choudhari R, Dhole T Mol Genet Genomic Med. 2020; 8(6):e1124.

PMID: 32212330 PMC: 7284032. DOI: 10.1002/mgg3.1124.

References

Van Dyke R, Wang L, Williams P . Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008; 198(11):1599-608. PMC: 2737265. DOI: 10.1086/593022. View

Kool M, de Haas M, Scheffer G, Scheper R, Van Eijk M, Juijn J . Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57(16):3537-47. View

Nagpal M, Tayal V, Kumar S, Gupta U . Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. Indian J Med Sci. 2012; 64(6):245-52. View

Deng Y, Newman B, Dunne M, Silburn P, Mellick G . Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson's disease. Neurosci Lett. 2004; 366(3):326-31. DOI: 10.1016/j.neulet.2004.05.061. View

Hitzl M, Klein K, Zanger U, Fritz P, Nussler A, Neuhaus P . Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003; 304(2):524-30. DOI: 10.1124/jpet.102.043547. View

Mukonzo J, Nanzigu S, Rekic D, Waako P, Roshammar D, Ashton M . HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet. 2011; 50(8):531-40. DOI: 10.2165/11592660-000000000-00000. View

Busti A, Hall R, Margolis D . Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004; 24(12):1732-47. DOI: 10.1592/phco.24.17.1732.52347. View

Bandara L, Kennedy S . Toxicoproteomics -- a new preclinical tool. Drug Discov Today. 2002; 7(7):411-8. DOI: 10.1016/s1359-6446(02)02211-0. View

Sasaki T, Hirota T, Ryokai Y, Kobayashi D, Kimura M, Irie S . Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function. Drug Metab Pharmacokinet. 2011; 26(4):374-86. DOI: 10.2133/dmpk.dmpk-10-rg-103. View

10.

Gotanda K, Tokumoto T, Hirota T, Fukae M, Ieiri I . Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene. Br J Clin Pharmacol. 2015; 80(5):1236-7. PMC: 4631197. DOI: 10.1111/bcp.12654. View

11.

Cascorbi I . Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112(2):457-73. DOI: 10.1016/j.pharmthera.2006.04.009. View

12.

Ieiri I, Higuchi S, Sugiyama Y . Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009; 5(7):703-29. DOI: 10.1517/17425250902976854. View

13.

Greenland S . The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980; 112(4):564-9. DOI: 10.1093/oxfordjournals.aje.a113025. View

14.

Ma Q, Lu A . Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2):437-59. DOI: 10.1124/pr.110.003533. View

15.

Borst P, Evers R, Kool M, Wijnholds J . A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92(16):1295-302. DOI: 10.1093/jnci/92.16.1295. View

16.

Samet J, Cheng D, Libman H, Nunes D, Alperen J, Saitz R . Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007; 46(2):194-9. PMC: 2247363. DOI: 10.1097/QAI.0b013e318142aabb. View

17.

Zhou S, Di Y, Chan E, Du Y, Chow V, Xue C . Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008; 9(8):738-84. DOI: 10.2174/138920008786049302. View

18.

Singh H, Lata S, Choudhari R, Dhole T . Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity. Mol Genet Genomic Med. 2020; 8(6):e1124. PMC: 7284032. DOI: 10.1002/mgg3.1124. View

19.

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B . Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004; 363(9417):1253-63. DOI: 10.1016/S0140-6736(04)15997-7. View

20.

Takechi T, Hirota T, Sakai T, Maeda N, Kobayashi D, Ieiri I . Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene. Drug Metab Dispos. 2018; 46(5):628-635. DOI: 10.1124/dmd.117.079061. View